$277 Million is the total value of Opaleye Management Inc.'s 49 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| STXS | New | STEREOTAXIS INC | $14,286,000 | – | 4,070,000 | +100.0% | 5.17% | – |
| TPTX | New | TURNING POINT THERAPEUTICS INC | $10,810,000 | – | 287,500 | +100.0% | 3.91% | – |
| CARA | New | CARA THERAPEUTICS INC | $8,043,000 | – | 440,000 | +100.0% | 2.91% | – |
| SWAV | New | SHOCKWAVE MED INC | $4,789,000 | – | 160,000 | +100.0% | 1.73% | – |
| QTRX | New | QUANTERIX CORP | $4,063,000 | – | 185,000 | +100.0% | 1.47% | – |
| NLTX | New | NEOLEUKIN THERAPEUTICS INC | $2,836,000 | – | 995,000 | +100.0% | 1.03% | – |
| FTSV | New | FORTY SEVEN INC | $2,729,000 | – | 425,000 | +100.0% | 0.99% | – |
| NXTC | New | NEXTCURE INC | $2,622,000 | – | 85,000 | +100.0% | 0.95% | – |
| RDUS | New | RADIUS HEALTH INC | $1,931,000 | – | 75,000 | +100.0% | 0.70% | – |
| New | APTOSE BIOSCIENCES INC | $1,501,000 | – | 720,000 | +100.0% | 0.54% | – | |
| FLXN | New | FLEXION THERAPEUTICS INC | $1,439,000 | – | 105,000 | +100.0% | 0.52% | – |
| CCXI | New | CHEMOCENTRYX INC | $1,356,000 | – | 200,000 | +100.0% | 0.49% | – |
| EDAP | New | EDAP TMS SAsponsored adr | $1,347,000 | – | 300,000 | +100.0% | 0.49% | – |
| ITCI | New | INTRA CELLULAR THERAPIES INC | $1,270,000 | – | 170,000 | +100.0% | 0.46% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $717,000 | – | 140,000 | +100.0% | 0.26% | – |
| ASMB | New | ASSEMBLY BIOSCIENCES INC | $492,000 | – | 50,000 | +100.0% | 0.18% | – |
| PRTO | New | PROTEON THERAPEUTICS INC | $14,000 | – | 54,000 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.